Actively Recruiting
Phase I Study of Oral AC676 for Safety and Effectiveness in Adults with Relapsed or Refractory B-Cell Cancers
Led by Accutar Biotechnology Inc · Updated on 2025-10-02
60
Participants Needed
9
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating AC676, an investigational oral drug that targets BTK, in adult participants with relapsed or refractory B-cell malignancies such as Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Marginal Zone Lymphoma, or Waldenstrm Macroglobulinemia. This Phase I, first-in-human, open-label study aims to find a safe and recommended dose, assess safety, study how the drug is processed in the body, and evaluate early signs of effectiveness. Participants will receive assigned doses of AC676 taken orally in repeated 28-day cycles. The study includes a dose-escalation phase to determine the maximum tolerated dose or recommended Phase II dose. Treatment details and dosing frequency are standardized in each cycle to monitor drug effects and safety. During the trial, researchers will closely observe participants for any dose-limiting toxicities, treatment-related side effects, and lab abnormalities over approximately 18 months. They will collect blood samples to analyze drug levels and monitor response using measures such as objective response rate, duration and time to response, disease control rate, and progression-free survival. The total study duration includes ongoing safety and effectiveness assessments, ensuring comprehensive evaluation of AC676 in this patient group.
CONDITIONS
Brief Title
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Research Team
A
Accutar Biotechnology
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here